HX treatment significantly reduced FFA-induced disruption of lipid metabolism, oxidative stress, and inflammatory responses in AML12 cells and inhibited lipid synthesis in the SREBF1/FASN/ACACA pathway, thereby ameliorating NAFLD symptoms and protecting the liver (Figure 9). Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.